VanEck JP Morgan EM Local Currency Bond ETF vs 10X Genomics Inc — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.47, while 10X Genomics Inc trades at $42.71 (market cap $5.81B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMLC | TXG | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $26.59 | $45.80 |
52-Week Low | $24.83 | $11.34 |
Market Cap | — | $5.81B |
Enterprise Value | — | $5.35B |
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $25.47, showing minimal daily movement with a slight decline of 0.04%. Technical indicators signal a bullish trend with moving averages supporting upward momentum, while oscillators remain neutral. The ETF maintains consistent dividend payments of $0.14 per share throughout 2026, providing steady income. Recent news highlights growing institutional interest in emerging market bonds as investors seek yield above Treasury rates.
The outlook for EMLC appears favorable given the Federal Reserve's accommodative stance and emerging market debt's attractive yield premium. However, currency risk and capital erosion concerns persist as short interest has surged 73%, indicating skepticism about long-term sustainability despite the 6.1% trailing yield.
TXG is trading at $45.80, up 9.65% today, showing strong momentum despite mixed analyst sentiment. The stock exhibits bullish technical signals with positive moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company continues to report revenue growth with improving margins, narrowing losses from -$166M in 2022 to -$44M in 2025. Recent developments include strategic acquisitions and research collaborations that strengthen its life sciences technology position.
The outlook remains cautiously optimistic as TXG demonstrates operational improvement and strategic positioning in genomics technology. Key opportunities include continued margin expansion and platform adoption, while risks involve persistent profitability challenges and competitive pressures. Analyst consensus shows divided opinions with a $37.71 price target below current levels, suggesting potential near-term volatility despite long-term growth prospects.
Trailing returns across standard periods
Latest headlines on both assets
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →